One Nucleus

One Nucleus

One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster.

Telephone: +44 (0)1223 896 450
Address: The Portway, Granta Park, Little Abington
Postcode: CB21 6GS
Country: United Kingdom
Website: http://www.onenucleus.com
Membership type:Corporate 6-20 (£250+VAT pa)

Organisation History

Established in 1997, and formerly known as ERBI, One Nucleus is a not-for-profit, membership organisation owned by its members and located in Cambridge and London – the centre of Europe’s leading life science and healthcare cluster.

More than 500 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’s mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

London and Cambridge

One Nucleus was formed in April 2010 by the merger of two regional lifescience networks – Cambridge-based ERBI and the London Biotechnology Network (LBN).  Together we form a commercial, clinical and academic powerhouse.  London and Cambridge are home to at least 60% of the UK’s life science industry base, four of the UK’s five Academic Health Science Centres and three of the world’s top six universities. The merger of ERBI and LBN recognises that the Cambridge-London network is an international life science “super cluster”.

The merger, driven by requests from ERBI and LBN members, results in several member benefits including:

  • A large pool of companies to support business-to-business interaction
  • Membership of a cluster of international size, relevance and visibility
  • One membership providing discounted entry to events in London and Cambridge
  • Economies of scale supporting our group purchasing scheme 
  • An expanded training programme focused on the needs of members
One Nucleus Training Courses for the Life Science Sectors

One Nucleus Training Courses for the Life Science Sectors

One Nucleus recognises that a company’s employees are its most valuable asset. Many rapidly growing companies overlook the need for ongoing training of their staff.

Derek Jones

One Nucleus announces new director

One Nucleus, the Cambridge based not-for-profit membership organisation for the London-East of England life sciences and healthcare cluster, is delighted to announce the appointment of Derek Jones as a Non-Executive Director. Derek is Chief Executive of Babraham Bioscience Technologies Ltd (BBT), the organisation responsible for the development and management of the Babraham Research Campus.

8 March 2018Read in full

ONe Nucleus logo

Join One Nucleus's Cambridge-based BioTuesday to discuss neurodegenerative diseases

Neurodegenerative diseases are incurable conditions in which nerve cells gradually degenerate, or die, for reasons that are not yet understood. Neurodegenerative diseases include Alzheimer’s, Parkinson's, Huntington's, Motor Neurone disease, Creutzfeldt-Jakob and Multiple Sclerosis, many of which give rise to dementia.

27 February 2018Read in full

One Nucleus appoints new Chief Executive

One Nucleus, the not-for-profit membership organisation for international life science and healthcare companies, is delighted to announce that Tony Jones, currently Director of Business Development at One Nucleus, is to become the company’s new Chief Executive.

18 July 2017Read in full

One Nucleus announce new Director

One Nucleus, the Cambridge based not-for-profit membership organisation for international life science and healthcare companies, is delighted to announce the appointment of Linda Summerton as a Director. Linda is Chief Executive of Immodulon and a Senior Partner with TranScrip Partners.

13 February 2017Read in full

PharmaVentures becomes latest Partner of One Nucleus

PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally.

14 January 2015Read in full

United Life Sciences to advance UK bioscience and publish UK Life Sciences Manifesto

Four leading life science membership organisations, the BioIndustry Association (BIA), Bionow, BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members and the wider UK sector.

9 October 2014Read in full

One Nucleus highlights for Spring 2014

One Nucleus highlights for Spring 2014

Harriet Fear, CEO of One Nucleus, writes:

11 April 2014Read in full

Genesis conference banner

An Introduction to Genesis 2013

Now in its 13th year, One Nucleus's hugely popular Genesis conference is constantly evolving to provide an efficient and dynamic conference for delegates, speakers and exhibitors.

20 September 2013Read in full

Record funding available for international trade missions to complement deals via One Nucleus

It is excellent news for One Nucleus members and the wider life sciences sector to hear that the Government is committing more financial assistance than ever before to assist eligible UK organisations who wish to join international trade missions to biotech events this autumn.

21 August 2013Read in full

One Nucleus invites you to register for Life Science Leadership Series

There has never been a time when the phrase ‘Cash is King’ has played more heavily on the minds of life science company executives.

5 August 2013Read in full

From Discovery to Clinic: Creating a Comprehensive and Efficient Development Operation

22 Nov 2018The Nucleus Chesterford Research Park Little Chesterford

Building on the success of last year’s “Getting Ready for Phase 1” event, this event will delve into the challenges facing the pharmaceutical industry to achieve clinical success. The pharmaceutical industry continues to experience decreasing productivity and high levels of attrition.

Partnering to Defeat Cancer

23 Nov 2018The Cambridge Building Babraham Research Campus

The ICR is one of the world's most influential cancer research organisations. Our discoveries have led to many new treatments for people with cancer, and we consistently rank at or near the top of national and international rankings of academic innovation, impact on society and research excellence.

Genesis 2018

13 Dec 2018QEII Conference Centre, Westminster, London

Driving success in Life Science & Healthcare: Convergence of Technology, Investment and People